pharma news today glp-1 obesity drug What is the pipeline for future medications for obesity? The GLP-1 Revolution: How Next-Generation

About 11% of the global eligible population of 1.3 billion people could be on obesity drugs by that time, especially as research suggests other potential benefits of obesity drugs in the treatment of other diseases, according to estimates published by Morgan Stanley Research earlier this year

Acid Stability: Gastric acidity destabilizes their molecular structure

As medications like semaglutide and liraglutide continue reshaping obesity treatment, an important question emerges: Will these drugs eventually replace bariatric surgery

Three reports to date suggest that VTA and NAc GLP-1Rs induced suppression of food intake and reward is not associated with visceral illness (Dossat et al., 2011

The new drugs, which were originally developed to treat diabetes, are targeting the biology that makes weight so hard to lose and keep off: They dial down hunger in the brain, slow gastric emptying, and improve post-meal insulin signaling

This information could be valuable in the decision to proceed with RSI (93.5%) vs cancelling the case (3.5%)